CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
- Proceeds will expand visugromab’s late-stage clinical development into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications
- Round brings on board new international biotech investors, Canaan Partners, Bioqube Ventures, Omega Funds, Forbion Growth Fund and Gilde Healthcare to support direct path towards registration for visugromab
Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius Biocapital III also participated in the round. The proceeds will fund the expansion of the company’s broad Phase 2b development of visugromab into randomized Phase 2b studies in select checkpoint naïve frontline and second-line treatment settings. Visugromab has already demonstrated outstanding anti-tumor activity in combination with checkpoint inhibitor treatment.